Glenmark Pharmaceuticals will be conducting a Phase III trial on a nitric oxide nasal spray, which it claims is effective in treatment of Covid-19.
The company had sought emergency approval for import and marketing of the nasal spray from the drug regulator last week. However, the subject expert Committee (SEC) under the drug regulator recommended Glenmark to conduct the Phase III trial.
Glenmark has joined hands with the Canadian company named Sanotize.
“The firm presented their proposal for grant of emergency approval for import and marketing the drug product before the committee. After detailed deliberation, the committee recommended that the firm should conduct Phase III clinical trial in Indian patients and accordingly, clinical trial protocol should be submitted for review by the committee,” the minutes of the meeting.
The company said that they will continue to evaluate various in-licensing opportunities across our their segments.
The company said that they will continue to lead various in . We have always led from the front in the fight against the Covid19 pandemic which is demonstrated by the strong support Fabiflu has received from doctors and patients in the treatment of mild to moderate Covid19. We are exploring various partnerships including the one with Sanotize which can help in protecting the Indian population from the SARS-COV-2 virus and reducing the impact of this pandemic on our society”.
The nasal spray works by killing the virus largely in the upper airways, preventing it from spreading to the lungs.
